JP2021526138A5 - - Google Patents
Info
- Publication number
- JP2021526138A5 JP2021526138A5 JP2020565354A JP2020565354A JP2021526138A5 JP 2021526138 A5 JP2021526138 A5 JP 2021526138A5 JP 2020565354 A JP2020565354 A JP 2020565354A JP 2020565354 A JP2020565354 A JP 2020565354A JP 2021526138 A5 JP2021526138 A5 JP 2021526138A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- mtor inhibitor
- individual
- nanoparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675110P | 2018-05-22 | 2018-05-22 | |
| US62/675,110 | 2018-05-22 | ||
| US201962810290P | 2019-02-25 | 2019-02-25 | |
| US62/810,290 | 2019-02-25 | ||
| US201962820842P | 2019-03-19 | 2019-03-19 | |
| US201962820838P | 2019-03-19 | 2019-03-19 | |
| US62/820,838 | 2019-03-19 | ||
| US62/820,842 | 2019-03-19 | ||
| PCT/US2019/033372 WO2019226685A1 (en) | 2018-05-22 | 2019-05-21 | Methods and compositions for treating pulmonary hypertension |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021526138A JP2021526138A (ja) | 2021-09-30 |
| JP2021526138A5 true JP2021526138A5 (https=) | 2022-05-27 |
| JP7561628B2 JP7561628B2 (ja) | 2024-10-04 |
Family
ID=68615837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565354A Active JP7561628B2 (ja) | 2018-05-22 | 2019-05-21 | 肺高血圧症を処置するための方法および組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210085621A1 (https=) |
| EP (1) | EP3810091A4 (https=) |
| JP (1) | JP7561628B2 (https=) |
| KR (1) | KR20210024471A (https=) |
| CN (1) | CN112423737A (https=) |
| AU (1) | AU2019274516B2 (https=) |
| BR (1) | BR112020023431A2 (https=) |
| CA (1) | CA3100905A1 (https=) |
| IL (1) | IL278814A (https=) |
| MX (2) | MX2020012478A (https=) |
| NZ (1) | NZ770290A (https=) |
| SG (1) | SG11202011462SA (https=) |
| TW (1) | TW202015659A (https=) |
| WO (1) | WO2019226685A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| ES3009356T3 (en) | 2015-06-29 | 2025-03-26 | Abraxis Bioscience Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| KR102936433B1 (ko) * | 2019-03-19 | 2026-03-09 | 아브락시스 바이오사이언스, 엘엘씨 | 질환의 치료를 위한 mTOR 억제제 및 알부민을 포함하는 나노입자의 피하 투여 |
| BR112022007710A2 (pt) | 2019-10-28 | 2022-07-12 | Abraxis Bioscience Llc | Composições farmacêuticas de albumina e rapamicina |
| KR20220120823A (ko) | 2021-02-24 | 2022-08-31 | 주식회사 만도 | 랙구동형 동력 보조 조향장치 |
| CN114732789B (zh) * | 2022-05-05 | 2023-08-22 | 中国药科大学 | 一种用于治疗肺动脉高压的复方长效递药系统及其制备 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| CA2509365C (en) | 2002-12-09 | 2012-08-07 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| US20090130163A1 (en) | 2005-02-18 | 2009-05-21 | Abraxis Bio Scoence, Inc. | Drugs With Improved Hydrophobicity For Incorporation in Medical Devices |
| KR20070114753A (ko) | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| EP3527202A1 (en) | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| EP2131821B1 (en) | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| RU2732908C2 (ru) * | 2014-10-07 | 2020-09-24 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии |
| KR20240144442A (ko) * | 2015-06-29 | 2024-10-02 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물에 대한 바이오마커 |
| JP2018521058A (ja) * | 2015-06-29 | 2018-08-02 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法 |
| CN107921050A (zh) * | 2015-06-29 | 2018-04-17 | 阿布拉科斯生物科学有限公司 | 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法 |
| ES3009356T3 (en) * | 2015-06-29 | 2025-03-26 | Abraxis Bioscience Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| EP3518923A4 (en) * | 2016-09-28 | 2020-06-17 | Abraxis BioScience, LLC | METHOD FOR TREATING MITOCHONDRIAL AND METABOLIC DISORDERS |
-
2019
- 2019-05-21 TW TW108117571A patent/TW202015659A/zh unknown
- 2019-05-21 CN CN201980048031.5A patent/CN112423737A/zh active Pending
- 2019-05-21 JP JP2020565354A patent/JP7561628B2/ja active Active
- 2019-05-21 KR KR1020207036401A patent/KR20210024471A/ko not_active Ceased
- 2019-05-21 BR BR112020023431-1A patent/BR112020023431A2/pt unknown
- 2019-05-21 MX MX2020012478A patent/MX2020012478A/es unknown
- 2019-05-21 CA CA3100905A patent/CA3100905A1/en active Pending
- 2019-05-21 WO PCT/US2019/033372 patent/WO2019226685A1/en not_active Ceased
- 2019-05-21 AU AU2019274516A patent/AU2019274516B2/en not_active Expired - Fee Related
- 2019-05-21 SG SG11202011462SA patent/SG11202011462SA/en unknown
- 2019-05-21 EP EP19807397.5A patent/EP3810091A4/en active Pending
- 2019-05-21 NZ NZ770290A patent/NZ770290A/en unknown
-
2020
- 2020-11-18 IL IL278814A patent/IL278814A/en unknown
- 2020-11-19 US US16/953,167 patent/US20210085621A1/en active Pending
- 2020-11-20 MX MX2024010373A patent/MX2024010373A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021526138A5 (https=) | ||
| JP4938905B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JP2023088944A5 (https=) | ||
| Vorhies et al. | Drug treatment of pulmonary hypertension in children | |
| US20100267735A1 (en) | Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors | |
| CN102006875A (zh) | 吡铂和贝伐单抗治疗结直肠癌的用途 | |
| CN1516588A (zh) | 用于局部眼科应用的溴莫尼定和噻吗洛尔的组合 | |
| CN1856339A (zh) | 肺动脉高血压症治疗的伊洛前列素联合疗法 | |
| JP2002529405A (ja) | 心臓血管系疾患による発病率及び死亡率減少のためのアンギオテンシン変換酵素阻害薬及びアルドステロン拮抗薬の併用療法 | |
| JP2020502261A5 (https=) | ||
| JP2022502492A5 (https=) | ||
| CN115803028A (zh) | 用于治疗慢性肾病的齐泊腾坦和达格列净的组合 | |
| JP2017128610A (ja) | 併用ａｌｓ療法 | |
| US20240016814A1 (en) | Method of treating hypertension | |
| US20050080018A1 (en) | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction | |
| US6635648B2 (en) | Combination therapy using sympathetic nervous system antagonists and endothelin antagonists | |
| US10576083B2 (en) | Method of treating pulmonary arterial hypertension | |
| WO2015069839A1 (en) | Combination therapy for treating pulmonary hypertension | |
| CN108472333A (zh) | 组合 | |
| CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 | |
| RU2020142051A (ru) | Способы и композиции для лечения легочной гипертензии | |
| TW201806599A (zh) | 用於快速開始抗抑鬱作用之給藥方案 | |
| JP6420923B1 (ja) | 医薬 | |
| CN1976708A (zh) | 包含bcrp抑制剂和4－(4－甲基哌嗪－1－基甲基)－n－[4－甲基－3－(4－吡啶－3－基)嘧啶－2－基氨基)苯基]－苯甲酰胺的组合 | |
| WO2025259699A1 (en) | Compositions and method for treating retinal degeneration |